New study may shed light on how parasite strain diversity can impact Chagas disease progression

Boehringer In­gel­heim is pay­ing Ochre Bio $35 mil­lion in up­front and near-term pay­ments to dis­cov­er new treat­ments for chron­ic liv­er dis­eases like meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis.

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls, and more. This week, we look in­to